about
Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrastComplications of antiretroviral therapy initiation in hospitalised patients with HIV-associated tuberculosisPresentation and outcome of tuberculous meningitis in a high HIV prevalence setting.Reduced referral and case fatality rates for severe symptomatic hyperlactataemia in a South African public sector antiretroviral programme: a retrospective observational study.Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis.AIDS-related mycoses: the way forward.Neutrophil-associated central nervous system inflammation in tuberculous meningitis immune reconstitution inflammatory syndrome.Detection of High Cerebrospinal Fluid Levels of (1→3)-β-d-Glucan in Cryptococcal MeningitisThe effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis.Rapid microbiological screening for tuberculosis in HIV-positive patients on the first day of acute hospital admission by systematic testing of urine samples using Xpert MTB/RIF: a prospective cohort in South Africa.HIV-tuberculosis-associated immune reconstitution inflammatory syndrome is characterized by Toll-like receptor and inflammasome signalling.Corticosteroid therapy, vitamin D status, and inflammatory cytokine profile in the HIV-tuberculosis immune reconstitution inflammatory syndromeCerebrospinal Fluid Culture Positivity and Clinical Outcomes After Amphotericin-Based Induction Therapy for Cryptococcal Meningitis.Anemia, Blood Transfusion Requirements and Mortality Risk in Human Immunodeficiency Virus-Infected Adults Requiring Acute Medical Admission to Hospital in South Africa.Human Immune Response Varies by the Degree of Relative Cryptococcal Antigen Shedding.Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome.Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial.Preventing Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in High-Risk Patients: Protocol of a Randomized Placebo-Controlled Trial of Prednisone (PredART Trial).HIV-Related Medical Admissions to a South African District Hospital Remain Frequent Despite Effective Antiretroviral Therapy Scale-Up.Flow Cytometry To Assess Cerebrospinal Fluid Fungal Burden in Cryptococcal MeningitisHIV-Associated Mycobacterium tuberculosis Bloodstream Infection Is Underdiagnosed by Single Blood Culture.Clinical management of tuberculosis and HIV-1 co-infectionMonocyte deactivation is associated with mortality in HIV-associated cryptococcal meningitisFalse rifampicin resistant results using Xpert MTB/RIF on urine samples in hospitalised HIV-infected patientsClinical, microbiologic, and immunologic determinants of mortality in hospitalized patients with HIV-associated tuberculosis: A prospective cohort studyEarly antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosisDiagnostic accuracy of a novel tuberculosis point-of-care urine lipoarabinomannan assay for people living with HIV: A meta-analysis of individual in- and outpatient data
P50
Q24620256-0A4250AB-79A0-48F6-8266-B8F0FD70A7F3Q28486096-92E9B13D-AFA0-464C-8E56-C2A9352A89F2Q33916426-680C9FF0-6958-4EE1-8A16-8A5C1FFA0E3CQ33968248-7B7C3CC7-ABAF-43F8-8927-67E4866611E1Q34024416-B021591E-8D51-40D0-A21F-8630A577F61DQ34030928-46FC67E3-9E92-4F70-A644-B0F186FD60A4Q34488659-3141123C-37D6-4E57-A3D0-603F00DC9F6CQ35072106-83003606-9DE3-40B8-9EC4-3FEC1D7B7678Q35635476-3731A6CD-186C-4F65-9FEB-BCA3FDD0BC99Q35746807-FF608E47-FC66-4EFA-B239-3DC319274F84Q36129630-2AE01BBD-EE33-4283-8F7F-FED03D4538D8Q36218302-4525FF38-AB05-42D7-810B-6DBDEDBE9ED3Q36407524-DC9245BD-C94B-46DF-BD78-6D5F82B62685Q36409322-38FA6523-80AD-4C33-99AC-52F6B68FECC9Q36488971-2F03F226-F067-4794-A5A4-3B54BA28C888Q36517790-3484011B-F32A-450A-94C0-CBB6237EC868Q36806209-B5634650-C6AB-40FC-8138-312F280B0F76Q37250893-2A227302-82A0-47B7-AC2B-7031D18F1ACBQ37328357-9A2804A8-ACFE-4B68-840B-B1520654013EQ38637694-686A2E2C-525C-43DE-B541-E34881E055C0Q50042305-BB1A3B3E-6F41-41C8-A3C2-793B219F44B1Q57827529-5F2F3781-632C-491C-A36F-C5B3897B3B0FQ58214203-998AAFED-50CA-436D-9D0D-29F1499D15FEQ90171109-342857EC-4786-4553-AE1F-DF806085E27DQ91650621-1859BC23-A9E8-497F-8573-371E92C937AAQ92486406-8EE9F3D5-A8F7-440C-82C9-CA546AD19C98Q94479704-761FBCB9-4666-4F09-8432-4881599633E6
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Charlotte Schutz
@ast
Charlotte Schutz
@en
Charlotte Schutz
@es
Charlotte Schutz
@nl
Charlotte Schutz
@sl
type
label
Charlotte Schutz
@ast
Charlotte Schutz
@en
Charlotte Schutz
@es
Charlotte Schutz
@nl
Charlotte Schutz
@sl
prefLabel
Charlotte Schutz
@ast
Charlotte Schutz
@en
Charlotte Schutz
@es
Charlotte Schutz
@nl
Charlotte Schutz
@sl
P106
P21
P31
P496
0000-0001-8329-6158